Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171120 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CFTRCA12CA9GAA | |
| SCHEMBL543814 | 0.74 | CFTR (0.38) | ALDH1A1CFTRLMNAPOLB | |
| SCHEMBL544381 | 0.72 | CFTR (0.38) | ALDH1A1CFTRLMNAPOLB | |
| SCHEMBL543542 | 0.72 | CFTR (0.38) | ALDH1A1CFTRLMNAPOLBNPSR1 | |
| SCHEMBL14181778 | 0.69 | CFTR (0.33) | CFTR | |
| SCHEMBL17554695 | 0.68 | CFTR (0.38) | ALDH1A1CFTR | |
| SCHEMBL543535 | 0.67 | ALDH1A1 (0.47) | ALDH1A1GAA | |
| SCHEMBL7868294 | 0.60 | KDM4E (0.36) | ALDH1A1CFTRLMNAGAAPOLB | |
| SCHEMBL8071793 | 0.59 | ALDH1A1 (0.40) | ALDH1A1CASP3CA2CA9LMNA | |
| SCHEMBL170913 | 0.58 | CASP3 (0.85) | ALDH1A1CASP3CYP3A4CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2388000-B1 | Neuroprotectant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2016-04-06 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2077836-B1 | AMYLOID BETA DEPOSITION INHIBITOR CONTAINING SPIRO-HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KK (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2388001-B1 | Age retardant containing heterocyclic compound having specific structure | ZENYAKU KOGYO KK (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9089561-B2 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| WO-2009107401-A1 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2009-09-03 | — | — | WO | disclosed |
| EP-2077836-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | disclosed |
| EP-2077835-A2 | AN ALZHEIMER'S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008047951-A2 | AN ALZHEIMER' S DISEASE PROGRESSION INHIBITOR CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047952-A2 | ANTIDEPRESSANT, NEUROPROTECTANT, AMYLOID BETA DEPOSITION INHIBITOR OR AGE RETARDANT CONTAINING HETEROCYCLIC COMPOUND | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-04-24 | — | — | WO | disclosed |
| EP-1357124-B1 | HETEROCYCLIC COMPOUNDS AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103158-A1 | spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2'-indan]; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, GRN | ALDH1A1 116/4885CFTR 4516/4885CASP3 824/4885 |
| US-20080103157-A1 | 3,3-dibenzylimidazo[1,2-a]pyridin-2(3H)-one; antidepressant, neuroprotectant, antiaging agent; manic depressive psychoses, obsessive-compulsive disorder; orally | PSEN1, PSEN2, BDNF | ALDH1A1 159/4885CFTR 4797/4885CASP3 308/4885 |
| US-20140171452-A1 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | PSEN1, GAP43, PSEN2 | ALDH1A1 905/4885CFTR 4873/4885CASP3 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.